Posted by Michael Wonder on 05 Oct 2021
Venetoclax comes close to gaining support from NICE
4 October 2021 - A proposal from AbbVie for a Cancer Drugs Fund listing may get it over the line.
The NICE Appraisal Committee recognised that venetoclax plus azacitidine is a promising new treatment, but was not persuaded that there is sufficient evidence of clinical and cost effectiveness to recommend it for routine commissioning for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.
Given the uncertainties, the Committee considered that venetoclax plus azacitidine may be suitable for use in the Cancer Drugs Fund.
